Scienture Holdings Enters Material Agreement, Discloses Financial Obligations
Ticker: SCNX · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1382574
| Field | Detail |
|---|---|
| Company | Scienture Holdings, Inc. (SCNX) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.00001, $12,222,222 m, $3,333,333, $3,000,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Scienture Holdings (formerly TRxADE HEALTH) filed an 8-K detailing a new material agreement, financial obligations, and equity sales.
AI Summary
Scienture Holdings, Inc. (formerly TRxADE HEALTH, INC.) entered into a material definitive agreement on November 22, 2024. The company also disclosed the creation of a direct financial obligation and unregistered sales of equity securities. This filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements and financial obligations, which could impact the company's financial health and stock performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Scienture Holdings, Inc. (company) — Registrant
- TRxADE HEALTH, INC. (company) — Former company name
- November 22, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Scienture Holdings, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What type of financial obligation was created by Scienture Holdings, Inc.?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant.
Were there any unregistered sales of equity securities by Scienture Holdings, Inc.?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 22, 2024.
What was Scienture Holdings, Inc. formerly known as?
Scienture Holdings, Inc. was formerly known as TRxADE HEALTH, INC., TRXADE GROUP, INC., and XCELLINK INTERNATIONAL INC.
Filing Stats: 2,514 words · 10 min read · ~8 pages · Grade level 13.1 · Accepted 2024-11-26 16:10:33
Key Financial Figures
- $0.00001 — ch registered Common stock, par value $0.00001 per share SCNX The Nasdaq Stock Mar
- $12,222,222 m — ntures") in a principal amount of up to $12,222,222 million, divided into up to three separat
- $3,333,333 — res in an aggregate principal amount of $3,333,333 (the "First Closing Debentures"). The F
- $3,000,000 — Arena Investors for a purchase price of $3,000,000, representing an original issue discoun
- $100,000 — Dawson James in an amount not to exceed $100,000. The Securities Purchase Agreement, De
- $50,000,000 — o direct the Investor to purchase up to $50,000,000 in shares of the Company's common stock
Filing Documents
- form8-k.htm (8-K) — 72KB
- ex10-1.htm (EX-10.1) — 435KB
- ex10-2.htm (EX-10.2) — 183KB
- ex10-3.htm (EX-10.3) — 194KB
- ex10-4.htm (EX-10.4) — 46KB
- ex10-5.htm (EX-10.5) — 124KB
- ex10-6.htm (EX-10.6) — 95KB
- ex10-7.htm (EX-10.6) — 296KB
- ex10-8.htm (EX-10.8) — 47KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001493152-24-047804.txt ( ) — 1973KB
- meds-20241122.xsd (EX-101.SCH) — 3KB
- meds-20241122_lab.xml (EX-101.LAB) — 34KB
- meds-20241122_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 26, 2024, the Company issued a press release announcing the Offering. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto is being furnished under Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Securities Purchase Agreement between the Company and the Arena Investors, dated as of November 22, 2024. 10.2 Form of 10% Original Issue Discount Secured Convertible Debenture. 10.3* Security Agreement between the Company and Arena Investors, dated November 25, 2024. 10.4 Guarantee Agreement between Scienture, LLC and Arena Investors, dated November 25, 2024. 10.5 Registration Rights Agreement between the Company and the Arena Investors, dated November 25, 2024. 10.6 Placement Agency Agreement between the Company and Dawson James, dated November 25, 2024. 10.7* Purchase Agreement between the Company and Arena Business Solutions Global SPC II, Ltd, dated as of November 25, 2024. 10.8 First Amendment of Loan and Security Agreement between the Company, NVK Finance, LLC, Scienture, LLC, Srivatsav, LLC, and Shankar Hariharan, dated as of November 22, 2024. 99.1 Press Release, dated November 26, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). * Exhibits and Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Com
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCIENTURE HOLDINGS, INC. By: /s/ Surendra Ajjarapu Surendra Ajjarapu Chief Executive Officer Date: November 26, 2024